By Ahmed Besheer, Head Formulation Development, Lonza
Innovations in formulations and injection devices improve compliance and quality of life for patients using new antibody formats.
The field of biologics is undergoing a significant change as it increases its focus on identifying new diseases to target, novel constructs to treat those diseases and innovative administration devices that include self-administration technologies to improve compliance and patient quality of life.
Patients who have diseases that demand regular administration of these new antibody treatments, on a monthly or bi-monthly basis, will see the significant benefits from these self-administration innovations, as their lives will not be highly impacted from constant travel to the doctor or the hospital. These formulation and device innovations will also have a positive impact on how well patients are able, or willing, to comply with the administration schedule as it becomes less disruptive to their lives.